Merck | Home
At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
Discover Job Opportunities at Merck | Merck Careers
Explore current job opportunities at Merck. Learn more about careers in Business Support, Clinical, Engineering, Information Technology, Research & Development, Manufacturing and Marketing.
Who we are - Merck.com
Merck aspires to be the premier research-intensive biopharmaceutical company in the world. Learn about our commitment to save and improve lives.
Your job search results | Merck Careers
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA. This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward ...
Products list - Merck.com
For information about Merck’s products and services including the reporting of an Adverse Event or Product Quality Complaint with a specific Merck product, please call the Merck National Service Center.
Contact us - Merck.com
Merck's U.S. headquarters, worldwide office, adverse event, investors, media, supplies and animal health contact information.
Company fact sheet - Merck.com
2023年12月31日 · Merck is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. View the list of products marketed in the U.S.
Our Q3 2024 financial results - Merck.com
2024年10月31日 · Merck’s Q3 2024 financial results represent strong progress across the business and our diverse pipeline. Our company announced worldwide sales of $16.7 billion, an increase of 4% from Q3 2023.
Investor relations - Merck.com
Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023. “Merck has begun 2024 with continuing momentum in our business.
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE …
2024年8月29日 · Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with stereotactic body radiotherapy (SBRT) for the treatment of patients with stage I or II (stage IIB N0, M0) non-small cell lung cancer (NSCLC), including those who are medically inoperable or have refused ...